Adibelivir

Adibelivir (IM-250) is an orally active helicase-primase inhibitor. Adibelivir is effective against HSV infection and reduces reactivation of latent HSV. Adibelivir inhibits HSV-1 infection in Vero cells (IC50: ~20 nM) . Adibelivir can be used for the study of recurrent herpes disease[1][2].

Product Specifications

CAS Number

[2305750-23-4]

Product Name Alternative

IM-250

UNSPSC

12352005

Target

HSV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/im-250.html

Purity

99.94

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

FC(C=CC(F)=C1)=C1C(C=C2)=CC=C2CC(N(C3=NC(C)=C([S@@](C)(=N)=O)S3)C)=O

Molecular Formula

C20H19F2N3O2S2

Molecular Weight

435.51

References & Citations

[1]Bernstein DI, et al. Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV. Antiviral Res. 2023 Nov;219:105733. |[2]Uhlig N, et al. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model. Antiviral Res. 2021 Nov;195:105190.